BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24680675)

  • 1. Pharmacological modulation of abnormal involuntary DOI-induced head twitch response in male DBA/2J mice: I. Effects of D2/D3 and D2 dopamine receptor selective compounds.
    Rangel-Barajas C; Malik M; Vangveravong S; Mach RH; Luedtke RR
    Neuropharmacology; 2014 Aug; 83():18-27. PubMed ID: 24680675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological modulation of abnormal involuntary DOI-induced head twitch response movements in male DBA/2J mice: II. Effects of D3 dopamine receptor selective compounds.
    Rangel-Barajas C; Malik M; Mach RH; Luedtke RR
    Neuropharmacology; 2015 Jun; 93():179-90. PubMed ID: 25698528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of the sigma-1 receptor selective compound LS-1-137 on the DOI-induced head twitch response in mice.
    Malik M; Rangel-Barajas C; Mach RH; Luedtke RR
    Pharmacol Biochem Behav; 2016 Sep; 148():136-44. PubMed ID: 27397487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen.
    Canal CE; Olaghere da Silva UB; Gresch PJ; Watt EE; Sanders-Bush E; Airey DC
    Psychopharmacology (Berl); 2010 Apr; 209(2):163-74. PubMed ID: 20165943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range.
    Baba S; Enomoto T; Horisawa T; Hashimoto T; Ono M
    J Pharmacol Sci; 2015 Mar; 127(3):326-31. PubMed ID: 25837930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors.
    Zhang W; Bymaster FP
    Psychopharmacology (Berl); 1999 Jan; 141(3):267-78. PubMed ID: 10027508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C57BL/6J mice exhibit reduced dopamine D3 receptor-mediated locomotor-inhibitory function relative to DBA/2J mice.
    McNamara RK; Levant B; Taylor B; Ahlbrand R; Liu Y; Sullivan JR; Stanford K; Richtand NM
    Neuroscience; 2006 Nov; 143(1):141-53. PubMed ID: 16938406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT
    de la Fuente Revenga M; Jaster AM; McGinn J; Silva G; Saha S; González-Maeso J
    ACS Chem Neurosci; 2022 Aug; 13(16):2436-2448. PubMed ID: 35900876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dopamine D3 antagonists on PPI in DBA/2J mice or PPI deficit induced by neonatal ventral hippocampal lesions in rats.
    Zhang M; Ballard ME; Kohlhaas KL; Browman KE; Jongen-Rêlo AL; Unger LV; Fox GB; Gross G; Decker MW; Drescher KU; Rueter LE
    Neuropsychopharmacology; 2006 Jul; 31(7):1382-92. PubMed ID: 16395300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats.
    Willins DL; Meltzer HY
    J Pharmacol Exp Ther; 1997 Aug; 282(2):699-706. PubMed ID: 9262333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists.
    Schreiber R; Brocco M; Audinot V; Gobert A; Veiga S; Millan MJ
    J Pharmacol Exp Ther; 1995 Apr; 273(1):101-12. PubMed ID: 7714755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model.
    Canal CE; Booth RG; Morgan D
    Neuropharmacology; 2013 Jul; 70():112-21. PubMed ID: 23353901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral evidence for differential adaptation of the serotonergic system after acute and chronic treatment with (+/- )-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) or ketanserin.
    Darmani NA; Martin BR; Glennon RA
    J Pharmacol Exp Ther; 1992 Aug; 262(2):692-8. PubMed ID: 1501117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
    Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Substituted
    Lee B; Taylor M; Griffin SA; McInnis T; Sumien N; Mach RH; Luedtke RR
    Molecules; 2021 May; 26(11):. PubMed ID: 34073405
    [No Abstract]   [Full Text] [Related]  

  • 16. A study of the structure-affinity relationship in SYA16263; is a D
    Onyameh EK; Bricker BA; Eyunni SVK; Voshavar C; Gonela UM; Ofori E; Jenkins A; Ablordeppey SY
    Bioorg Med Chem; 2021 Jan; 30():115943. PubMed ID: 33338898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bitropic D3 Dopamine Receptor Selective Compounds as Potential Antipsychotics.
    Luedtke RR; Rangel-Barajas C; Malik M; Reichert DE; Mach RH
    Curr Pharm Des; 2015; 21(26):3700-24. PubMed ID: 26205291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. F15063, a potential antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A) agonist and D(4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice.
    Assié MB; Bardin L; Auclair A; Consul-Denjean N; Sautel F; Depoortère R; Newman-Tancredi A
    Naunyn Schmiedebergs Arch Pharmacol; 2007 Jun; 375(4):241-50. PubMed ID: 17453175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological investigation of new equatorial (β) stereoisomers of 3-aminotropane arylamides with atypical antipsychotic profile.
    Stefanowicz J; Słowiński T; Wróbel MZ; Herold F; Gomółka AE; Wesołowska A; Jastrzębska-Więsek M; Partyka A; Andres-Mach M; Czuczwar SJ; Łuszczki JJ; Zagaja M; Siwek A; Nowak G; Żołnierek M; Bączek T; Ulenberg S; Belka M; Turło J
    Bioorg Med Chem; 2016 Sep; 24(18):3994-4007. PubMed ID: 27377863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds.
    Luedtke RR; Mishra Y; Wang Q; Griffin SA; Bell-Horner C; Taylor M; Vangveravong S; Dillon GH; Huang RQ; Reichert DE; Mach RH
    ACS Chem Neurosci; 2012 Dec; 3(12):1050-62. PubMed ID: 23259040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.